Close Menu

UMass

NEW YORK (GenomeWeb News) – A team from the Universities of Massachusetts and Pennsylvania is finding new contributors to genetically complex common diseases or traits using a statistical strategy that harvests locus-level information from existing genome-wide association study data.

RNAi researcher Anastasia Khvorova has joined the RNA Therapeutics Institute at the University of Massachusetts Medical School as a professor of molecular medicine.

NEW YORK (GenomeWeb News) – There are hundreds of genomic regions that are uniquely regulated in the human brain as compared to other primates, an international team of researchers reporte

The University of Utah this month took steps to keep its RNAi intellectual property lawsuit on track after the defendants in the case sought a stay of proceedings, arguing that discovery in the litigation should proceed while certain jurisdictional issues are resolved.

NEW YORK (GenomeWeb News) – A new study is adding heft to the notion that cytoskeletal pathway alterations can spur amyotrophic lateral sclerosis, or ALS, commonly known as Lou Gehrig's Disease.

Silence Therapeutics said this week that it plans to raise as much as £5.7 million ($8.8 million) through the issuance of up to around 940 million new ordinary shares.

Roughly one week after a US District Court rejected the efforts of University of Massachusetts officials to have an intellectual property lawsuit filed against them dismissed, the UMass defendants have filed an appeal with a federal court to re-examine the issue.

A Massachusetts District Court this week denied motions to dismiss an intellectual property-ownership lawsuit filed by the University of Utah against Alnylam Pharmaceuticals and several University of Massachusetts officials, among others, telling the defendants that they have not

The University of Utah last week fired back at a bid by University of Massachusetts officials to have an RNAi technology intellectual property lawsuit dismissed, arguing that the court hearing the case — and not the US Supreme Court, as the officials contend — is the appropriate

Pages

Bloomberg reports that vaccine developers won't have to conduct large trials of updated vaccines or vaccine boosters aimed at new viral variants.

The SARS-CoV-2 variant uncovered in California may be more transmissible and partially evade vaccine-induced antibody response, the Los Angeles Times reports.

Francis deSouza, the CEO of Illumina, calls for a global SARS-CoV-2 genomics surveillance network, according to the Financial Times.

In PNAS this week: immunotherapy for hard-to-treat breast cancers, effects of oncogenic histone H3K36M mutations, and more.